We also assessed the prognostic value of STON2 expression in EOC patient subgroups stratified by serum biomarker levels such as CA153, CA199, intraperitoneal metastasis, ascites with tumor cells, neoadjuvant chemotherapy, intraperitoneal recurrence and so on (Figure 4). Here, STON2 is linked to neoplasm.